Movement Alert｜Argenx SE Rises 3.08% in Regular Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target

Market Focus06-24

On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.

On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target price of $1,219, implying approximately 31% upside from current levels. According to FactSet data, the stock carries an average analyst rating of Buy with a consensus target price of $1,064.53. BNP Paribas's target sits meaningfully above market consensus, providing a positive boost to market sentiment.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product efgartigimod generated $1.3 billion in revenue in Q1, representing 62.5% year-over-year growth. The company reported net income of $366 million, with R&D expenses of $400 million reflecting continued pipeline investment. The next earnings report is scheduled for July 23 pre-market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177328570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 00:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177328570","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 3.08% in Regular Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target","media":"Market Focus","content":"<p><p>On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.</p><p>On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target price of $1,219, implying approximately 31% upside from current levels. According to FactSet data, the stock carries an average analyst rating of Buy with a consensus target price of $1,064.53. BNP Paribas's target sits meaningfully above market consensus, providing a positive boost to market sentiment.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product efgartigimod generated $1.3 billion in revenue in Q1, representing 62.5% year-over-year growth. The company reported net income of $366 million, with R&D expenses of $400 million reflecting continued pipeline investment. The next earnings report is scheduled for July 23 pre-market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 3.08% in Regular Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 3.08% in Regular Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 00:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.</p><p>On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target price of $1,219, implying approximately 31% upside from current levels. According to FactSet data, the stock carries an average analyst rating of Buy with a consensus target price of $1,064.53. BNP Paribas's target sits meaningfully above market consensus, providing a positive boost to market sentiment.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product efgartigimod generated $1.3 billion in revenue in Q1, representing 62.5% year-over-year growth. The company reported net income of $366 million, with R&D expenses of $400 million reflecting continued pipeline investment. The next earnings report is scheduled for July 23 pre-market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1177328570","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177328570","pubTimestamp":1782232793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势提示|Argenx SE常规交易涨3.08%法巴启动跑赢大盘评级目标1219美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target price of $1,219, implying approximately 31% upside from current levels. According to FactSet data, the stock carries an average analyst rating of Buy with a consensus target price of $1,064.53. BNP Paribas's target sits meaningfully above market consensus, providing a positive boost to market sentiment.Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product efgartigimod generated $1.3 billion in revenue in Q1, representing 62.5% year-over-year growth. The company reported net income of $366 million, with R&D expenses of $400 million reflecting continued pipeline investment. The next earnings report is scheduled for July 23 pre-market.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177328570","isCrawlerRequest":true}